Gastrointestinal stromal tumors (GISTs) are rare mesenchymal
sarcomas and the gold-standard treatment is represented by
tyrosine kinase inhibitors (TKIs). Unfortunately, first-line treatment with the TKI
imatinib usually promotes partial response or stable disease rather than a complete response, and resistance appears in most patients. Adaptive mechanisms are immediately relevant at the beginning of
imatinib therapy, and they may represent the reason behind the low complete response rates observed in GISTs. Concurrently, resistant subclones can silently continue to grow or emerge de novo, becoming the most representative populations. Therefore, a slow evolution of the primary
tumor gradually occurs during
imatinib treatment, enriching heterogeneous
imatinib resistant clonal subpopulations. The identification of secondary KIT/PDGFRA mutations in resistant GISTs prompted the development of novel multi-targeted TKIs, leading to the approval of
sunitinib,
regorafenib, and
ripretinib. Although
ripretinib has broad anti-KIT and -PDGFRA activity, it failed to overcome
sunitinib as second-line treatment, suggesting that
imatinib resistance is more multifaceted than initially thought. The present review summarizes several biological aspects suggesting that heterogeneous adaptive and resistance mechanisms can also be driven by KIT or PDGFRA downstream mediators, alternative
kinases, as well as non-coding RNAs, which are not targeted by any TKI, including
ripretinib. This may explain the modest effect observed with
ripretinib and all anti-GIST agents in patients.